ADU-S100

  CAY-27901-1 1 mg

Data Sheet:     SDS:    

---

1638750-95-4  

A solid  

≥98%  

734,5  

-20  

-20  

1460  

---

Description

 

ADU-S100 is a cyclic dinucleotide STING agonist.{38806} It induces IFN-β-dependent reporter activity in HEK293T cells expressing human STING, the human STING variants STING HAQ, STING REF, STING AQ, STING Q, or mouse STING when used at a concentration of 10 µM. Intratumoral administration of ADU-S100 (50 µg/tumor per day for three days) reduces tumor growth in wild-type, but not in Sting1-/-, mice in a B16/F10 murine melanoma model. It decreases primary and secondary tumor volume in a 4T1 murine breast cancer model of tumor rechallenge when intratumorally administered. Unilateral intratumoral administration of ADU-S100 reduces tumor volumes in a bilateral CT26 murine colorectal cancer model. It increases tumor infiltration of natural killer (NK) cells, CD4+ T cells, and CD8+ T cells, as well as increases immune cell-induced tumor necrosis, in a GL261 murine glioma model when intratumorally administered at a dose of 50 µg/tumor.{67835}

 

---